You are viewing: US Biobanking Market analysis
Part of: Biobanking Market (Global)

The US Biobanking Market was valued at $1931.1 Million in 2025 and projected to reach to $2908.8 Million by 2030, representing a compound annual growth rate of 8.5%. The US biobanking market is positioned for sustained growth through 2030, driven by the healthcare sector's strategic pivot toward precision medicine and personalized therapeutics.

US Biobanking Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Biobanking Market Trends and Insights

  • This expansion reflects the US healthcare sector's increasing investment in precision medicine, genomic research, and personalized treatment development.
  • The US biobanking infrastructure benefits from advanced regulatory frameworks, substantial R&D funding, and a strong network of academic and commercial biobanks supporting clinical trials and drug discovery initiatives. Driving this growth, the US market is characterized by rising demand for biospecimens, enhanced data analytics capabilities, and integration of artificial intelligence in sample management.
  • The US biobanking ecosystem encompasses academic medical centers, commercial biobanks, and hospital-based repositories, all contributing to the sector's 8.5% compound annual growth rate through 2030.
  • Strategic partnerships between US pharmaceutical companies and biobanking facilities are accelerating the development of targeted therapies and advancing the precision medicine landscape across the nation..

Key Market Statistics

  • CAGR (2025-2030) 8.5% CAGR
  • Market Size, 2025 ~USD 1931.1 Million
  • Forecast, 2030 ~USD 2908.8 Million
  • Country US

US Biobanking Market Overview

Market Valuation Growth :

The US biobanking market is valued at $1,931.1 million in 2025 and is projected to reach $2,908.8 million by 2030, representing a robust 8.5% CAGR driven by precision medicine adoption.

Precision Medicine Investment :

US healthcare providers are significantly increasing investments in precision medicine and genomic research, positioning biobanking as a critical infrastructure component for personalized treatment development.

Regulatory Framework Advantage :

The US benefits from advanced regulatory frameworks and substantial federal R&D funding, creating a favorable environment for biobanking innovation and standardization across healthcare institutions.

Clinical Research Expansion :

Growing demand from academic medical centers, pharmaceutical companies, and biotech firms for high-quality biological samples is accelerating biobanking infrastructure development across the US.

US Biobanking Market Dynamics

  • Federal funding initiatives, including NIH grants and precision medicine programs, continue to support biobank expansion and modernization.
  • Healthcare institutions are increasingly recognizing biobanking as essential infrastructure for clinical research and drug development, with growing adoption among academic medical centers and hospital networks. Key growth catalysts include advancing genomic sequencing technologies, increasing patient awareness of biobanking benefits, and regulatory clarity from FDA and other governing bodies.
  • The market will likely see consolidation among smaller biobanks and increased investment in digital infrastructure for sample tracking and data management.
  • Strategic partnerships between biobanks, pharmaceutical companies, and research institutions will further accelerate market expansion through 2030..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The US biobanking market will grow from $1,931.1M (2025) to $2,908.8M (2030) at an 8.5% CAGR.
    • US biobanking is driven by precision medicine adoption, genomic research expansion, and AI-enabled sample management systems.
    • The US market benefits from robust regulatory frameworks, substantial federal R&D funding, and a mature network of academic and commercial biobanks.
    • Strategic partnerships between US pharmaceutical companies and biobanking facilities are accelerating drug discovery and personalized therapy development.

    Biobanking Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment SOFTWARE (Offering)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.1% from 2025 to 2030
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 7.65 (2025)
    Revenue Forecast (Billions) ~USD 11.82 (2030)
    Segments Covered Offering, Type, Operation Type, Workflow, Sample Type, Ownership, Application, End User

    US Biobanking Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services
    • Software

    By Type

    • Alarm & Monitoring Systems
    • Clinical Research
    • Consumables
    • Cryogenic Storage Systems
    • Equipment
    • Freezers & Refrigerators
    • Life Science Research
    • Life Sciences Research
    • Other Equipment & Accessories
    • Other Services
    • Physical Biobanking Services
    • Temperature & Humidity Control Systems
    • Thawing Equipment
    • Virtual Biobanking Services

    By Operation Type

    • Automated Equipment
    • Automated Operations
    • Manual Equipment
    • Manual Operations

    By Workflow

    • Sample Analysis
    • Sample Collection & Storage
    • Sample Processing
    • Transport & Logistics

    By Sample Type

    • Biological Fluids
    • Blood Products
    • Human Waste Products
    • Nucleic Acids
    • Solid Tissues & Organs
    • Stem Cells & Cell Lines

    By Ownership

    • Academic & Research Institution Biobanks
    • Hybrid/Ppp Model
    • National/Regional Agencies
    • Other Ownership Models
    • Private/ Commercial Biobanks

    By Application

    • Diagnostic Applications
    • Other Applications
    • Research Applications
    • Therapeutic Applications

    By End User

    • Academic & Research Institutes
    • Biobanks
    • Cros
    • Hospitals & Diagnostic Laboratories
    • Pharma-Biotech Companies & Cros

    US: BIOBANKING PRODUCTS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    BIOBANKS1373.21410.81501.61616.217501903.220782277.98.7
    CROS397.8406.1429.5459.3494.2534579.3630.98
    TOTAL17711816.91931.12075.52244.22437.22657.32908.88.5

    US: BIOBANKING SERVICES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES189.3195.5212.4232.7256.1282.5312.334610.3
    HOSPITALS & DIAGNOSTIC LABORATORIES116.6119.9129.7141.5155.1170.4187.62079.8
    PHARMA-BIOTECH COMPANIES & CROS452.9469.2511.1561.9620.2686.3761845.610.6
    TOTAL758.8784.7853.2936.11031.41139.21260.91398.610.4

    Target Audience

    • Pharmaceutical & Biotech Companies : US-based and international pharma firms need biobanking market intelligence to identify sample sourcing opportunities, evaluate biobank partnerships, and plan clinical trial infrastructure investments.
    • Healthcare System Administrators : Hospital networks and academic medical centers require market data to justify biobanking infrastructure investments, benchmark against peer institutions, and develop precision medicine programs.
    • Biobanking Technology Vendors : Software, equipment, and service providers need US market insights to identify growth opportunities, understand customer requirements, and develop solutions aligned with precision medicine trends.
    • Investment & Private Equity Firms : Investors evaluating biobanking sector opportunities need comprehensive US market analysis, growth projections, and competitive dynamics to assess investment returns and portfolio positioning.
    • Research Institutions & Universities : Academic research centers need market intelligence to secure funding, establish biobanking partnerships with industry, and align research initiatives with precision medicine market demands.

    Key Companies in the US Biobanking Market

    CompanyHQOwnershipStrongest segments
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx and STx instruments,ExPERT GTx and VLx instruments,Disposable processing assemblies (PAs),
    HDFC BANKIndiaPublic CompanyRetail Banking (deposits, consumer and home loans, cards),Wholesale Banking (corporate, SME, supply chain, trade),Treasury and Markets (money market, derivatives, investments),
    STANDARD CHARTEREDUnited KingdomPrivate CompanyFinancial Markets (FX, rates, commodities, credit),Transaction Banking (trade, cash, liquidity, custody),Corporate & Structured Finance,
    YES BANKIndiaPublic CompanyRetail banking (deposits, cards, consumer loans),Corporate and wholesale banking,MSME and business banking,
    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITEDIndiaPublic CompanyVehicle Finance (CV, PV, 2W/3W, tractors, construction equipment),Loan Against Property (LAP) and SME Secured Loans,Home Loans and Home Extensions,
    AXIS MUTUAL FUNDIndiaPrivate CompanyActively managed equity funds,Hybrid and asset allocation funds,Debt and money market funds,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Diagnostic and Life Sciences,Healthcare Solutions (EMR, billing, pharmacy, wellness),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
    AVANTOR, INC.United StatesPublic CompanyMaterials and consumables,Equipment and instrumentation,Services and specialty procurements,
    CRYOPORTUnited StatesPublic CompanyLife Sciences Services (logistics, biostorage, bioservices, consulting),Life Sciences Products (cryogenic freezers, dewars, accessories),IoT and digital monitoring solutions,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    LABCORPUnited StatesPublic CompanyRoutine and chronic-disease diagnostics (chemistry, hematology, A1C, thyroid, PSA, urinalysis),Specialty and esoteric testing (gene-based, oncology, cardiovascular, endocrinology, infectious disease),Biopharma Laboratory Services and clinical trial support,
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    HAIER BIOMEDICALChinaPublic CompanyULT freezers and low-temperature storage,Pharmacy and vaccine refrigerators/freezers, cold rooms,Blood bank and transfusion chain equipment,
    HAMILTON COMPANYUnited StatesPublic Investment FirmFund-of-funds (primary and secondary),Direct credit,Direct and co-investments / buyouts,

    MAXCYTE, INC

    MAXCYTE, INC is a public company based in the United States that was founded in 1998 and currently employs 91 people.

    HDFC BANK

    HDFC BANK is a public company based in India that was founded in 1994 and currently employs 212,958 people.

    STANDARD CHARTERED

    STANDARD CHARTERED is a private company based in the United Kingdom that was founded in 1853 and currently employs 66,524 people.

    YES BANK

    YES BANK is a public company based in India that was founded in 2003 and currently employs 29,577 people.

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED is a public company based in India that was founded in 1978 and currently employs 51,320 people.

    AXIS MUTUAL FUND

    AXIS MUTUAL FUND is a private company based in India that was founded in 2009.

    THERMO FISHER SCIENTIFIC INC.

    THERMO FISHER SCIENTIFIC INC. is a public company based in the United States that was founded in 1956 and currently employs 125,000 people.

    PHC HOLDINGS CORPORATION

    PHC HOLDINGS CORPORATION is a public company based in Japan that was founded in 1948 and currently employs 8,647 people.

    QIAGEN

    QIAGEN is a public company based in the Netherlands that was founded in 1984 and currently employs 5,500 people.

    MERCK KGAA

    MERCK KGAA is a public company based in Germany that was founded in 1668 and currently employs 59,077 people.

    AVANTOR, INC.

    AVANTOR, INC. is a public company based in the United States that was founded in 1904 and currently employs 13,500 people.

    CRYOPORT

    CRYOPORT is a public company based in the United States that was founded in 1999 and currently employs 688 people.

    AGILENT TECHNOLOGIES, INC.

    AGILENT TECHNOLOGIES, INC. is a public company based in the United States that was founded in 1999 and currently employs 18,000 people.

    LABCORP

    LABCORP is a public company based in the United States that was founded in 1995 and currently employs 66,385 people.

    EUROFINS SCIENTIFIC

    EUROFINS SCIENTIFIC is a public company based in Luxembourg that was founded in 1987 and currently employs 65,694 people.

    HAIER BIOMEDICAL

    HAIER BIOMEDICAL is a public company based in China that was founded in 2005 and currently employs 2,945 people.

    HAMILTON COMPANY

    HAMILTON COMPANY is a public investment firm based in the United States that was founded in 1991 and currently employs 785 people.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise US market valuation ($1,931.1M in 2025) and verified 8.5% CAGR projections through 2030, enabling accurate financial forecasting and investment decision-making for US-focused biobanking initiatives.
    • Competitive Landscape Intelligence : Understand the US biobanking competitive environment, including key players, market consolidation trends, and differentiation strategies specific to American healthcare institutions and regulatory requirements.
    • Precision Medicine Opportunity Assessment : Identify high-growth segments within US precision medicine and genomic research sectors, including emerging applications in personalized oncology, rare disease research, and targeted drug development.
    • Regulatory & Compliance Insights : Access detailed analysis of US regulatory frameworks, FDA guidelines, HIPAA compliance requirements, and state-level biobanking regulations essential for market entry and operational planning.
    • Strategic Partnership Opportunities : Discover collaboration potential with US academic medical centers, pharmaceutical companies, biotech firms, and healthcare networks actively expanding biobanking capabilities and seeking technology partners.

    Frequently asked questions

    What is the current size of the US biobanking market?

    The US biobanking market is valued at $1,931.1 million in 2025 and is expected to reach $2,908.8 million by 2030.

    What is the growth rate of the US biobanking market?

    The US biobanking market is growing at a compound annual growth rate (CAGR) of 8.5% from 2025 to 2030.

    What are the main drivers of growth in the US biobanking market?

    Key drivers include increased precision medicine adoption, expansion of genomic research, AI-enabled sample management, and strategic partnerships between pharmaceutical companies and biobanking facilities in the US.

    Who are the primary participants in the US biobanking ecosystem?

    The US biobanking ecosystem includes academic medical centers, commercial biobanks, hospital-based repositories, pharmaceutical companies, and research institutions engaged in clinical trials and drug discovery.

    How does the US biobanking market compare to global trends?

    The US biobanking market grows at 8.5% CAGR, slightly below the global average of 9.1%, reflecting the US market's maturity and the rapid expansion of biobanking in emerging markets.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Biobanking Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Biobanking Market : Top-Down and Bottom-Up Approach

    Biobanking Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.

    Key Stakeholders

    • Academic & Research Institutes
    • Biobanks
    • Contract Research Organizations (CROs)
    • Market Research and Consulting Firms
    • Pharmaceutical and Biotechnology Companies
    • Regulatory Agencies
    • Venture Capitalists
    • Forensics Labs
    • Government organizations
    • Private research firms
    • Hospitals and Diagnostic Laboratories

    Report Objectives

    • To define, describe, and forecast the biobanking market by offering, equipment-operation type, service-ownership, product-sample type, application, product-end user, service-end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biobanking market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • Further breakdown of Rest of Europe biobanking market, by country
    • Further breakdown of Rest of Asia Pacific biobanking market, by country

    Comapany Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

     

    Get the Full Biobanking Market Report

    Full forecast, segment splits, and company analysis for all Biobanking Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status